CONCLUSIONS This case suggests possible value in performing molecular testing when a clinical picture does not correspond with what is expected for melanoma
Retatrutide also reduced pain in patients with knee osteoarthritis, with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores dropping by as much as 4.5 points, a 75.8% reduction with the 9 mg dose, compared with a 2.4 point (40.3%) reduction for placebo
In the first Phase 3 trial of the ACHIEVE program, orforglipron lowered A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand
Women of childbearing potential should use effective contraception during treatment, and semaglutide should be discontinued at least 2 months before a planned pregnancy
November 15th, 2024: Master complaint filed in Ozempic MDL consolidating claims against Novo Nordisk and Eli Lilly The multidistrict litigation (MDL) for GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, reached a significant milestone with the filing of a Master Complaint
A 2023 study published in Diabetes, Obesity, and Metabolism demonstrated that GLP-1 agonist users engaging in regular physical activity experienced better weight loss quality, retaining more muscle mass compared to those who did not exercise
